Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Available until 8/1/2024

Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.

Already Have An Account? Log in Now

story of the week

Journal Scan / Research · June 24, 2024

Long-Term Survival Outcomes With Trastuzumab Deruxtecan vs Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer

Nature Medicine




This abstract is available on the publisher's site.

Access this abstract now  

Additional Info

Disclosure statements are available on the authors' profiles:

Nature Medicine
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
Nat. Med. 2024 Jun 02;[EPub Ahead of Print], J Cortés, SA Hurvitz, SA Im, H Iwata, G Curigliano, SB Kim, JWY Chiu, JL Pedrini, W Li, K Yonemori, G Bianchini, S Loi, GS Borges, X Wang, T Bachelot, S Nakatani, S Ashfaque, Z Liang, A Egorov, E Hamilton

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading